Figure 3From: A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom Cost-effectiveness acceptability curves by subgroup. a: preterm infants <29 wGA. b: preterm infant’s 29–32 wGA. c: preterm infant’s 33–35 wGA. d: CLD infants. e: CHD infants.Back to article page